Key facts
- Dash (Discovery Tools (Healthcare))’s last known valuation is $61.0M (Jun 2025).
- It has raised $17.5M; the latest was Early Stage VC ($11.0M) in Jun 2025.
- Notable investors include Sequoia Capital, Drive Capital, Life Extension Ventures, Freestyle Capital, Companion-M — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Dash (Discovery Tools (Healthcare))
- ·The full record, as it builds
Funding rounds
No funding rounds for Dash (Discovery Tools (Healthcare)) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dash (Discovery Tools (Healthcare))
Developer of a clinical bioanalysis platform intended to offer tech-enabled services for drug development. The company's platform adapts a technology-first approach to developing critical services across the drug development lifecycle, aiming to build new capabilities that leverage AI, robotics, and fully integrated software to deliver GLP-compliant services, enabling users to automate critical steps, reduce costs, and shorten time to market without compromising on quality.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2024
- Website
- dash.bio/
- Ownership
- Privately Held (backing)
Dash (Discovery Tools (Healthcare)) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dash (Discovery Tools (Healthcare)) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dash (Discovery Tools (Healthcare)) in its N-PORT filings yet. We sweep new filings monthly.